摘要
目的探讨白细胞介素13在哮喘和慢性阻塞性肺疾病中的变化及临床意义。方法选择正常组30例,哮喘和慢性阻塞性肺疾病患者急性发作期、缓解期各30例,取静脉血,用ELISA方法分别测定血清和外周血单个核细胞培养的上清夜中IL-13的水平。同时测定一秒钟用力呼气容积及改变率(FEV1、FEV1改变率),并对结果进行统计学分析。结果哮喘急性发作期血清及外周单个核细胞(PBMC)诱生的IL-13、FEV1改变率显著高于哮喘缓解期(P<0.01)。两组均显著高于正常组(P<0.01)。直线相关分析结果表明:急性期血清和PBMC诱导的IL-13水平与FEV1改变率的关系(r=0.708和r=0.866,P<0.01)。缓解期血清和PBMC诱导的IL-13水平与FEV1改变率的关系(r=0.862和r=0.928,P<0.01)。COPD组急性期血清和PBMC中的IL-13水平、FEV1改变率显著高于缓解期(P<0.01),两组与正常组之比较,均有显著差异(P<0.01)。直线相关分析结果表明:急性期血清和PBMC诱导的IL-13水平与FEV1改变率的关系(r=0.396,P>0.05和r=0.647,P<0.01)。缓解期血清和PBMC诱导的IL-13水平与FEV1改变率的关系(r=0.347和r=0.331,P>0.05)。结论 IL-13参与了哮喘和慢性阻塞性肺疾病的形成,它可能是气道高反应性形成的原因之一。
Objective To explore the expression of interleukin-13 and the relationship with FEV1% in patients with asthma and chronic obstructive pulmonary disease.Methods The study group included 30 cases in remission stage and in active attack group separately.The venous blood was drawn,and the serum IL-13 was detected by ELISA method,at the same time FEV1% was measured.The results of determination were analyzed by SPSS.Results The serum and periphereral blood mononucleare cell（PBMC）-induced IL-13 and FEV1% from asthmatic patients in active attack were higher than those in remission stage（P0.01）.Both were higher than those of control group（P0.01）.Linear correlation analysis showed that the serumand PBMC-induced IL-13 were positivelycorrelated to the FEV1% in remission stage separately（r=0.862 and r=0.928,P0.01）,and in active attack（r=0.708 and r= 0.866,P0.01）.The serum and PBMC-induced IL-13 and FEV1% from COPD patients in active attack were higher than those in remission stage（P0.01）,both were higher than those of control group（P0.01）.Linear correlation analysis showed that the serum IL-13 level in active attack had no correlation to the FEV1%（r=0.396,P0.05）,but PBMC-induced IL-13 was positively correlated to the FEV1%（r=0.647,P0.01）.The serum and PBMC-induced IL-13 was not correlated to the FEV1% in remission stage respectively（r=0.347 and r=0.331,P0.05）.Conclusion IL-13 plays a role in pathology with asthma and chronic obstructive pulmonary disease,which may be one of the reasons formulating airway hyperresponsibility.
出处
《云南医药》
CAS
2010年第5期515-519,共5页
Medicine and Pharmacy of Yunnan
关键词
白细胞介素13
哮喘
慢性阻塞性肺疾病
气道高反应性
Interleukin-13
Asthma
Chronic obstructive pulmonary disease
Airway hyperresponsibility
